Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
P 1 (1)
P 2 (1)

Trial Status

Active Not Recruiting1
Unknown1

Clinical Trials (2)

Showing 2 of 2 trials
NCT05933265Phase 1Active Not Recruiting

Study of LP-184 in Patients With Advanced Solid Tumors

NCT04761744Phase 2UnknownPrimary

A Phase II Study of Nivolumab in Patients With Genetic Alterations in DNA Damage Repair and Response Who Progressed After Standard Treatment for Metastatic Solid Cancers

Showing all 2 trials

Research Network

Activity Timeline